title: The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease.
abstract: BACKGROUND
  Behçet disease is a systemic inflammatory disease of unknown aetiology. T cells in this disease proliferate vigorously in response to a specific peptide of heat shock protein (HSP) 60 in an antigen-specific fashion. Vascular endothelial cell growth factor (VEGF) is a cytokine participating in the inflammatory process. One of the prominent features of Behçet disease is vasculitis as a result of endothelial dysfunction. Antiphospholipid antibodies (APA) may play a role in the development of thrombosis by inhibiting production of prostacyclin by endothelial cells.
  
  
  OBJECTIVE
  To investigate the role of HSP60, VEGF and APA in Behçet disease and their relation to clinical manifestations and disease activity.
  
  
  METHODS
  Thirty patients with Behçet disease were included; 17 were in the active stage and 13 were in the inactive. Fifteen age- and sex-matched healthy subjects served as controls. Complete clinical examination and Doppler examination were done. Serum levels of HSP60, VEGF and APA were performed.
  
  
  RESULTS
  Serum levels of HSP60, VEGF and APA were significantly higher in patients than in controls; however, their level did not correlate with disease activity. The serum level of VEGF correlated significantly with the presence of vascular manifestations and ocular involvement. The serum level of APA was greater in patients with thrombosis. HSP60 has an important role in aetiopathogenesis of Behçet disease, which sheds new light on its autoimmune nature.
  
  
  CONCLUSIONS
  An elevated serum level of VEGF may be a risk factor for the development of ocular disease contributing to poor visual outcome.
authors.affiliation: Department of Medical Biochemistry, Faculty of Medicine, Kasr El Aini Hospital, Cairo University, Cairo, Egypt. olfatshaker@yahoo.com
authors.forename: O
authors.initials: O
authors.lastname: Shaker
authors.forename: M A
authors.initials: MA
authors.lastname: Ay El-Deen
authors.forename: H
authors.initials: H
authors.lastname: El Hadidi
authors.forename: B D
authors.initials: BD
authors.lastname: Grace
authors.forename: H
authors.initials: H
authors.lastname: El Sherif
authors.forename: A
authors.initials: A
authors.lastname: Abdel Halim
mesh_terms: D000293:Adolescent; D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000502:physiology*; D001528:Behcet Syndrome / Q000276:immunology*; D016022:Case-Control Studies; D018834:Chaperonin 60 / Q000502:physiology*; D016228:Endothelial Growth Factors / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology*
chemical_list: D017152:Antibodies, Antiphospholipid; D018834:Chaperonin 60; D016228:Endothelial Growth Factors; D042461:Vascular Endothelial Growth Factor A